<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965597</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1904</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <nct_id>NCT04965597</nct_id>
  </id_info>
  <brief_title>HCT Using Treosulfan for Bone Marrow Failure Diseases (BMT CTN 1904)</brief_title>
  <official_title>Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II study designed to evaluate the outcomes of&#xD;
      patients with bone marrow failure diseases (BMFD) undergoing HLA-matched related, HLA-matched&#xD;
      unrelated, or single HLA-class 1 allele or HLA-DQB1 antigen or allele mismatched unrelated&#xD;
      hematopoietic cell transplantation (HCT) using treosulfan-based conditioning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated with a preparative regimen of treosulfan (total dose 30-42 g/m2),&#xD;
      fludarabine (total dose 150 mg/m2), and Thymoglobulin (total dose 6 mg/kg). GVHD prophylaxis&#xD;
      will be with tacrolimus and methotrexate.&#xD;
&#xD;
      Patients will be followed for 1-year post-HCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS)</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>The primary endpoint is the incidence of 1-year GVHD free, EFS (GEFS). An event is defined as death due to any cause, graft rejection/failure, or 2nd HCT whichever occurs first. Grade III-IV acute GVHD and chronic GVHD (using NIH consensus criteria) requiring systemic immune suppression will be considered in this estimate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Day 100 post-HCT</time_frame>
    <description>Overall survival at day 100 after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months post-HCT</time_frame>
    <description>Overall survival at 6 months after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Overall survival at 1 year after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Event-free survival will be estimated at 12 months after HCT. Grade III-IV acute GVHD and chronic GVHD requiring systemic immune suppression will be considered in this estimate. An event is defined as death due to any cause, primary or secondary graft failure/rejection, or 2nd HCT whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Recovery: Neutrophil recovery</measure>
    <time_frame>Assessed up to 1 year post-HCT</time_frame>
    <description>Hematologic recovery will be assessed according to neutrophil recovery after transplant. Neutrophil recovery is defined as achieving an absolute neutrophil count (ANC) ≥ to 500/mm3 for 3 consecutive measurements on 3 different days. The first of the three days will be designated the day of neutrophil recovery. The competing event is death without neutrophil recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Recovery: Platelet recovery</measure>
    <time_frame>Day 100 post-HCT</time_frame>
    <description>Hematologic recovery will be assessed according to platelet counts recovery after transplant. Platelet recovery is defined as the first day of a minimum of 3 days that the patient has a sustained platelet count ≥ 20,000/mm3 with no platelet transfusions in the preceding 7 days. The first day of sustained platelet count above these thresholds will be designated the day of platelet engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism (CD3 and Myeloid)</measure>
    <time_frame>Day 28 post-HCT</time_frame>
    <description>Proportions of patients with full (&gt;95%), mixed (5-95%), or rejection (&lt;5%) myeloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism (CD3 and Myeloid)</measure>
    <time_frame>Day 100 post-HCT</time_frame>
    <description>Proportions of patients with full (&gt;95%), mixed (5-95%), or rejection (&lt;5%) myeloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism (CD3 and Myeloid)</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Proportions of patients with full (&gt;95%), mixed (5-95%), or rejection (&lt;5%) myeloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary graft failure/rejection</measure>
    <time_frame>Day 42 post-HCT</time_frame>
    <description>Defined as never achieving ANC ≥ 500/μL or never achieving ≥ 5% donor myeloid chimerism assessed by peripheral blood chimerism assays by day +42 post-HCT. Second infusion of hematopoietic cells is also considered indicative of primary graft failure by day +42 post-HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary graft failure/rejection post-HCT</measure>
    <time_frame>Assessed up to 1 year post-HCT</time_frame>
    <description>Defined as &lt; 5% donor myeloid chimerism in peripheral blood beyond day +42 post-HCT in patients with prior documentation of hematopoietic recovery with ≥ 5% donor cells by day +42 post-HCT. Second infusion of hematopoietic cells is also considered indicative of secondary graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV and grade III-IV GVHD at day 100</measure>
    <time_frame>Day 100 post-HCT</time_frame>
    <description>The cumulative incidences of acute grade II-IV and III-IV GVHD at day 100 after HCT will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV and grade III-IV GVHD at day 180</measure>
    <time_frame>Day 180 post-HCT</time_frame>
    <description>The cumulative incidences of acute grade II-IV and III-IV GVHD at day 100 after HCT will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>The cumulative incidence of chronic GVHD (using NIH consensus criteria) requiring systemic immune suppression at 1 year after HCT will be determined. Data will be collected directly from providers and chart review as defined by the NIH Consensus Conference Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-5 toxicities</measure>
    <time_frame>Day 30 post-HCT</time_frame>
    <description>Grade 3-5 toxicities by day 30 after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-5 toxicities</measure>
    <time_frame>Day 100 post-HCT</time_frame>
    <description>Grade 3-5 toxicities by day 100 after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 2-3 systemic infections</measure>
    <time_frame>6 months post-HCT</time_frame>
    <description>All microbiologically documented infections or significant infections requiring antibiotic/antifungal therapy occurring up to 6 months after HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Epstein Barr virus (EBV) reactivation requiring therapy</measure>
    <time_frame>Day 180 post-HCT</time_frame>
    <description>The incidence of EBV reactivation requiring therapy in the first 180 days after HCT, and of EBV-associated lymphoproliferative disorder in the first 180 days after HCT will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of EBV-associated lymphoproliferative disorder</measure>
    <time_frame>Day 180 post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT</measure>
    <time_frame>Up to day 180 post-HCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bone Marrow Failure Disorders</condition>
  <arm_group>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with a preparative regimen of treosulfan (total dose 30-42 g/m2), fludarabine (total dose 150 mg/m2), and Thymoglobulin (total dose 6 mg/kg). GVHD prophylaxis will be with tacrolimus and methotrexate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
    <other_name>Fluradosa</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin (Rabbit Anti-thymocyte Globulin; rATG)</intervention_name>
    <description>Given IV</description>
    <arm_group_label>treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patient must be ≥ 1.0 year of age and less than 50.0 years of age at the time of&#xD;
             enrollment (i.e. patient must have celebrated their 1st birthday when enrolled and&#xD;
             must NOT have celebrated their 50th birthday when enrolled; 49.99 years).&#xD;
&#xD;
             2. Underlying bone marrow failure disorders treatable by allogenic HCT.&#xD;
&#xD;
             a. Shwachman-Diamond syndrome i. Criteria for Diagnosis:&#xD;
&#xD;
               1. A pathogenic mutation(s) for Shwachman-Diamond syndrome&#xD;
&#xD;
               2. For those patients tested but lacking a genetic mutation they must meet both&#xD;
                  criteria a and b below:&#xD;
&#xD;
                    1. Exocrine pancreatic dysfunction as defined by at least one of the following:&#xD;
&#xD;
                  i. Pancreatic isoamylase below normal (age &gt;3 years old), OR ii. Fecal elastase&#xD;
                  &lt;200, AND b. Bone marrow failure as evidenced by at least one of the following:&#xD;
                  i. Intermittent or persistent neutropenia (absolute neutrophil count &lt; 1,500/μL),&#xD;
                  OR ii. Hypo-productive anemia with a hemoglobin concentration below the&#xD;
                  age-related adjusted norms, OR iii. Unexplained macrocytosis, OR iv. Platelet&#xD;
                  count &lt;150,000/μL without alternative etiology, OR v. Hypocellular bone marrow&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
             1. Severe neutropenia (ANC &lt;500/μL), OR 2. Severe anemia (hemoglobin &lt;8 g/dL) or&#xD;
             transfusion-dependent anemia, OR 3. Severe thrombocytopenia (platelet count&#xD;
             &lt;20,000/μL) or transfusion-dependent thrombocytopenia, OR 4. Additional clinical or&#xD;
             laboratory data may be considered for protocol eligibility following review by&#xD;
             protocol 1904 eligibility review committee (ERC). In addition, patients with severe or&#xD;
             recurrent infections will be reviewed by the ERC if they do not meet indications for&#xD;
             transplant listed above.&#xD;
&#xD;
             b. Diamond Blackfan anemia i. Criteria for Diagnosis:&#xD;
&#xD;
               1. A pathogenic mutation for Diamond Blackfan anemia&#xD;
&#xD;
               2. For those patients tested but lacking a genetic mutation the patient must meet&#xD;
                  criteria a and at least one of the criteria listed in b-f:&#xD;
&#xD;
                  a. History of deficiency of erythroid precursors in an otherwise cellular bone&#xD;
                  marrow AND, b. Reticulocytopenia, OR c. Elevated adenosine deaminase activity, OR&#xD;
                  d. Elevated hemoglobin F, OR e. Macrocytosis, OR f. Congenital anomalies ii.&#xD;
                  Indications for HCT:&#xD;
&#xD;
             1. RBC transfusion dependent anemia despite an adequate trial of steroids; OR 2.&#xD;
             Additional clinical or laboratory data may be considered for protocol eligibility&#xD;
             following review by protocol 1904 ERC.&#xD;
&#xD;
             c. Congenital Sideroblastic anemia i. Criteria for Diagnosis:&#xD;
&#xD;
               1. A pathogenic mutation(s) for sideroblastic anemia&#xD;
&#xD;
               2. For those patients tested but lacking a genetic mutation:&#xD;
&#xD;
                  a. Presence of ringed sideroblasts in the bone marrow excluding acquired causes&#xD;
                  of ringed sideroblasts such as lead poisoning &amp; zinc toxicity.&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
               1. Severe anemia (hemoglobin &lt;8 g/dL) or transfusion-dependent anemia OR&#xD;
&#xD;
               2. Additional clinical or laboratory data may be considered for protocol eligibility&#xD;
                  following review by protocol 1904 ERC.&#xD;
&#xD;
                  d. GATA2 mutation with associated marrow failure i. Criteria for Diagnosis:&#xD;
&#xD;
               1. A pathogenic mutation(s) for GATA2&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
               1. Severe neutropenia (ANC &lt;500/μL), OR&#xD;
&#xD;
               2. Severe anemia (hemoglobin &lt;8 g/dL) or transfusion-dependent anemia, OR&#xD;
&#xD;
               3. Severe thrombocytopenia (platelet count &lt;20,000/μL) or transfusion-dependent&#xD;
                  thrombocytopenia, OR&#xD;
&#xD;
               4. Additional clinical or laboratory data may be considered for protocol eligibility&#xD;
                  following review by protocol 1904 ERC. In addition, patients with severe or&#xD;
                  recurrent infections will be reviewed by the ERC if they do not meet the&#xD;
                  indications for transplant listed above.&#xD;
&#xD;
                  e. SAMD9 or SAMD9L disorders i. Criteria for Diagnosis:&#xD;
&#xD;
               1. A pathogenic mutation(s) for SAMD9 or SAMD9L&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
             1. Severe neutropenia (ANC &lt;500/μL), OR 2. Severe anemia (hemoglobin &lt;8 g/dL) or&#xD;
             transfusion-dependent anemia, OR 3. Severe thrombocytopenia (platelet count&#xD;
             &lt;20,000/μL) or transfusion-dependent thrombocytopenia, OR 4. Additional clinical or&#xD;
             laboratory data may be considered for protocol eligibility following review by&#xD;
             protocol 1904 ERC.&#xD;
&#xD;
             f. Congenital amegakaryocytic thrombocytopenia i. Criteria for Diagnosis:&#xD;
&#xD;
             1. A pathogenic mutation(s) for congenital amegakaryocytic thrombocytopenia. 2. For&#xD;
             those patients tested but lacking a genetic mutation the patient must meet criteria a&#xD;
             and b below:&#xD;
&#xD;
               1. Thrombocytopenia early in life, AND&#xD;
&#xD;
               2. History of bone marrow demonstrating megakaryocyte hypoplasia.&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
                    1. Severe thrombocytopenia (platelet count &lt;20,000/μL) or transfusion-dependent&#xD;
                       thrombocytopenia, OR&#xD;
&#xD;
                    2. Neutropenia defined as an ANC &lt;500/μL, OR&#xD;
&#xD;
                    3. Severe anemia (hemoglobin &lt;8 g/dL) or transfusion-dependent anemia, OR&#xD;
&#xD;
                    4. Additional clinical or laboratory data may be considered for protocol&#xD;
                       eligibility following review by protocol 1904 ERC.&#xD;
&#xD;
             g. Paroxysmal nocturnal hemoglobinuria (PNH) i. Criteria for Diagnosis:&#xD;
&#xD;
               1. PNH clone size in granulocytes &gt; 10%, AND&#xD;
&#xD;
               2. Complement mediated intravascular hemolysis with an elevated LDH (above&#xD;
                  institutional upper limits of normal)&#xD;
&#xD;
                  ii. Indications for HCT:&#xD;
&#xD;
               1. PNH with thrombosis despite adequate medical management, OR&#xD;
&#xD;
               2. PNH with intravascular hemolysis requiring transfusion support despite adequate&#xD;
                  medical management, OR&#xD;
&#xD;
               3. Additional clinical or laboratory data may be considered for protocol eligibility&#xD;
                  following review by protocol 1904 ERC. In addition, patients with PNH and&#xD;
                  cytopenias may be considered for the protocol eligibility following review by&#xD;
                  protocol 1904 ERC.&#xD;
&#xD;
                  h. An undefined BMFD: a patient with a BMFD for whom a genetic mutation&#xD;
                  responsible for their bone marrow failure phenotype has not been identified&#xD;
                  (excluding PNH) will be eligible for this clinical trial following approval by&#xD;
                  BMT CTN 1904 ERC.&#xD;
&#xD;
                  i. A BMFD with a known genetic mutation but not listed above will be eligible for&#xD;
                  this clinical trial following approval by BMT CTN 1904 ERC.&#xD;
&#xD;
                  Note: The following patients MUST be reviewed by the BMT CTN 1904 ERC in order to&#xD;
                  determine if they are eligible for this trial:&#xD;
&#xD;
                  a. All patients with Shwachman-Diamond syndrome, Diamond Blackfan anemia,&#xD;
                  congenital sideroblastic anemia, and congenital amegakaryocytic thrombocytopenia&#xD;
                  who lack a genetic mutation.&#xD;
&#xD;
                  b. All patients with an undefined BMFD: a patient with a BMFD for whom a genetic&#xD;
                  mutation responsible for their bone marrow failure phenotype has not been&#xD;
                  identified, excluding PNH.&#xD;
&#xD;
                  c. All patients with a BMFD and a known genetic mutation that is not listed above&#xD;
                  d. All patients with GATA2 mutation with associated marrow failure e. All&#xD;
                  patients with SAMD9 or SAMD9L disorders f. There may be circumstances where a&#xD;
                  treating physician will consider a transplant for a patient with a BMFD who does&#xD;
                  not meet all the criteria listed under &quot;indications for HCT&quot;. In these&#xD;
                  situations, treating physicians may submit their patient to the BMT CTN 1904 ERC&#xD;
                  for review in order to determine if the patient is eligible for this clinical&#xD;
                  trial based on additional clinical or laboratory information.&#xD;
&#xD;
                  g. Many patients with BMFD can have bone marrow evaluations that raise concern&#xD;
                  for possible myelodysplastic syndrome (MDS) including but not limited to&#xD;
                  dysplastic bone marrow evaluations or cytogenetic abnormalities. However, in&#xD;
                  patients with BMFD these findings are not necessarily diagnostic or consistent&#xD;
                  with MDS. Therefore, given the complexities of diagnosing MDS in patients with&#xD;
                  BMFD, all patients with bone marrow evaluations concerning for possible MDS&#xD;
                  should be submitted to the ERC for expert review to confirm or exclude MDS. This&#xD;
                  is particularly important as we do not want to exclude potentially eligible&#xD;
                  patients due to an incorrect diagnosis of MDS.&#xD;
&#xD;
             3. Patient and/or legal guardian must sign informed consent prior to initiation of&#xD;
             conditioning for BMT CTN 1904.&#xD;
&#xD;
             4. Females and males of childbearing potential must agree to practice 2 effective&#xD;
             methods of contraception at the same time or agree to abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with idiopathic aplastic anemia, Fanconi anemia, dyskeratosis congenita,&#xD;
             and congenital neutropenia.&#xD;
&#xD;
             2. Patients with MDS as defined by the World Health Organization (WHO) or leukemia.&#xD;
&#xD;
             3. Prior allogeneic transplant 4. Patient's weight ≤10.0 kg at time of study&#xD;
             enrollment 5. Lansky (patients &lt; 16 years of age) or Karnofsky (patients ≥16 years of&#xD;
             age) performance &lt;70% 6. Organ Dysfunction defined as follows:&#xD;
&#xD;
             a. Cardiac: i. Left ventricular ejection fraction &lt;50% by echocardiogram or&#xD;
             multi-gated acquisition (MUGA) scan.&#xD;
&#xD;
        ii. For patients unable to obtain a left ventricular ejection fraction, left ventricular&#xD;
        shortening fraction &lt;26%.&#xD;
&#xD;
        b. Pulmonary: i. DLCO (corrected/adjusted for hemoglobin), FEV1, and FVC &lt;50% predicted.&#xD;
        ii. For patients unable to perform pulmonary function tests (PFTs) due to age or&#xD;
        developmental delay: Oxygen saturation &lt;92% on room air.&#xD;
&#xD;
        iii. On supplemental oxygen. c. Renal: i. Estimated creatinine clearance &lt;60&#xD;
        mL/minute/1.73m2 (estimated per institutional practice).&#xD;
&#xD;
        ii. Dialysis dependent d. Hepatic: i. Conjugated bilirubin &gt; 2x upper limit of normal for&#xD;
        age (ULN, unless attributable to Gilbert's syndrome), or ii. AST or ALT &gt; 4x ULN for age,&#xD;
        or iii. Fulminant liver failure or cirrhosis 7. Iron overload - This exclusion criterion&#xD;
        only applies to patients who are considered at risk for hepatic or cardiac iron overload.&#xD;
        Therefore, not all patients enrolled on this protocol will undergo formal hepatic or&#xD;
        cardiac iron assessment.&#xD;
&#xD;
          1. For patients ≥ 18 years with a history of significant transfusions defined as ≥8&#xD;
             packed red blood cell transfusions per year for ≥1 year or have received ≥20 packed&#xD;
             red blood cell transfusions (lifetime cumulative) will require formal hepatic and&#xD;
             cardiac iron measurement. In addition, patients with a prior history of hepatic or&#xD;
             cardiac iron overload will also require formal assessment for iron overload. Patients&#xD;
             are excluded if:&#xD;
&#xD;
        i. Hepatic iron content ≥ 8 mg Fe/g dry weight by liver MRI using a validated methodology&#xD;
        (such as T2* MRI or ferriscan) or liver biopsy per institutional practice.&#xD;
&#xD;
        ii. Cardiac iron content &lt; 25 msec by cardiac T2* MRI. b. For patients &lt; 18 years old with&#xD;
        a history of significant transfusions defined as ≥8 packed red blood cell transfusions per&#xD;
        year for ≥1 year or have received ≥20 packed red blood cell transfusions (lifetime&#xD;
        cumulative) will require formal hepatic iron measurement. In addition, patients with a&#xD;
        prior history of hepatic iron overload will also require formal assessment for iron&#xD;
        overload. Patients are excluded if: i. Hepatic iron content ≥ 8 mg Fe/g dry weight by liver&#xD;
        MRI using a validated methodology (such as T2* MRI or ferriscan) or liver biopsy per&#xD;
        institutional practice.&#xD;
&#xD;
        8. Uncontrolled bacterial infection within 1 week of study enrollment. Uncontrolled is&#xD;
        defined as currently taking medication with no clinical improvement or progression on&#xD;
        adequate medical treatment.&#xD;
&#xD;
        9. Uncontrolled viral or fungal infection within 30 days of study enrollment. Uncontrolled&#xD;
        is defined as currently taking medication with no clinical improvement or progression on&#xD;
        adequate medical treatment.&#xD;
&#xD;
        10. Positive for HIV (human immunodeficiency virus). 11. Presence of clinically significant&#xD;
        anti-donor HLA-antibodies per institutional practice.&#xD;
&#xD;
        12. Prior solid organ transplant. 13. Patients with prior malignancies except resected&#xD;
        non-melanoma skin cancer or treated cervical carcinoma in situ.&#xD;
&#xD;
        14. Demonstrated lack of compliance with prior medical care as determined by referring&#xD;
        physician.&#xD;
&#xD;
        15. Females who are pregnant or breast-feeding. 16. Known hypersensitivity to treosulfan or&#xD;
        fludarabine. Known life-threatening reaction (i.e. anaphylaxis) to Thymoglobulin that would&#xD;
        prohibit use for the patient as this study requires use of the Thymoglobulin preparation of&#xD;
        anti-thymocyte globulin (ATG).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret MacMillan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Scott</last_name>
    <phone>240-599-5648</phone>
    <phone_ext>15648</phone_ext>
    <email>bmtctn1904@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Mendizabal, PhD</last_name>
    <email>amendizabal@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kimberly Arieli</last_name>
      <email>karieli@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Paibel Aguayo-Hiraldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kevin Magruder</last_name>
      <email>kevin.magruder@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin Shimano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Courtney Newbold</last_name>
      <email>Courtney.Newbold@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Jessica Knight-Perry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Judson Russell</last_name>
      <email>judson.russell@choa.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Leung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brandi Bratrude</last_name>
      <email>brandi.bratrude@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Lehmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Connie Varner</last_name>
      <email>convarne@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Vander Lugt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Merve Tekmen</last_name>
      <email>tekme002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret MacMillan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Murray</last_name>
      <email>Murraylm@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Heather Cameron</last_name>
      <email>heather.cameron@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Bambach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kirsten Fuller</last_name>
    </contact>
    <investigator>
      <last_name>Maria Cancio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Hopsital of NY</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amelia Halac</last_name>
      <email>dhalac@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Fish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erin Arbuckle</last_name>
      <email>erin.arbuckle@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Kurtzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Samantha (Sam) McBride</last_name>
      <email>samantha.mcbride@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Kasiani Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebecca Hulme</last_name>
      <email>hulmer@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia Hankins</last_name>
      <email>hankinsp@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Delia Darst</last_name>
      <email>delia.h.darst@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Jim Connelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>LaTarsha Williams</last_name>
      <email>ldwilliams1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Kris Mahadeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Jobe</last_name>
      <email>emilia.jobe@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Ghadir Sasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christina Wiedl</last_name>
      <email>cwiedl@vcu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Courtney Vandervlugt</last_name>
      <email>cvanderv@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin/Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Ruskiewicz</last_name>
      <email>eruszkiewicz@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Talano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Marrow Failure Disorders</keyword>
  <keyword>HSCT</keyword>
  <keyword>Treosulfan</keyword>
  <keyword>Unrelated donor</keyword>
  <keyword>Matched donor</keyword>
  <keyword>mismatched donor</keyword>
  <keyword>transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

